文献速递免疫规划

灭活或病毒载体SARS-CoV-2疫苗后中枢神经系统脱髓鞘疾病:病例系列

CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series.
PubMed 文献 · Vaccine · 2023-01-06

该病例系列回顾性收集了12例在接种COVID-19疫苗后6周内新发MS或NMOSD的患者,其中11例接种灭活疫苗、1例接种病毒载体疫苗,接种后数天内发病(首剂3例、第二剂8例、第三剂1例)。作者认为国药BBIBP-CorV与阿斯利康AZD1222疫苗可能是中枢神经系统脱髓鞘疾病的潜在诱因,但此类事件罕见且属巧合,不影响疫苗接种常规,需进一步研究明确机制与真实关联。

要点

  • 12例中MS 9例、临床孤立综合征1例、NMOSD 2例。
  • 接种灭活疫苗11例、病毒载体疫苗1例,首剂3例、第二剂8例、第三剂1例。
  • 中位年龄33.3岁(19–53岁),女性10例(83%)。

核心结论

  • 作者认为国药BBIBP-CorV与阿斯利康AZD1222疫苗可能是中枢神经系统脱髓鞘疾病的潜在诱因,但此类事件罕见且属巧合,不影响疫苗接种常规,这些表现不可否认并需认真关注,需进一步研究明确实际机制与真实关联。

研究设计与样本

  • 回顾性病例系列,收集12例接种COVID-19疫苗后6周内新发MS或NMOSD患者的医疗信息。

主要发现

  • 12例中MS 9例、临床孤立综合征1例、NMOSD 2例,接种灭活疫苗11例、病毒载体疫苗1例。
  • 发病在首剂后3例、第二剂后8例、第三剂后1例,均在接种后数天内。
  • 中位年龄33.3岁(范围19–53岁),女性10例(83%)。
  • 所有患者在接受3剂糖皮质激素后完全(5例)或部分(2例)恢复。
  • 常用药物为那他珠单抗、特立氟胺、富马酸二甲酯和利妥昔单抗,1例严重麻木症状患者使用干扰素β-1a。

临床怎么用

  • 作者认为疫苗接种常规不受这些罕见且巧合的事件影响,但这些表现不可否认并需认真关注。

局限性

  • 原文报告需进一步研究以明确实际机制与真实关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several reports have been documented in possible association with the administration of different severe acute respiratory coronavirus 2 (SARS-CoV-2) vaccines and central nervous system (CNS)demyelinating disorders, specifically post mRNA vaccines. We report twelve cases of developing Multiple sclerosis (MS) or Neuromyelitis Optica spectrum disorders (NMOSD) following neither the first nor second dose of inactivated or viral vector COVID-19 vaccine. METHODS: We retrospectively compiled twelve patients' medical information with a new onset of MS or NMOSD in their first six weeks following a COVID-19 vaccine. RESULTS: We report twelve cases of MS (n = 9), clinically isolated syndrome (CIS)(n = 1), and NMOSD (n = 2) following COVID-19 inactivated vaccines (n = 11) or viral vector vaccines (n = 1), within some days following either the first (n = 3), second dose (n = 8), or third dose (n = 1). Their median age was 33.3 years, ranging from 19 to 53 years. Ten were women (83 %). All patients fully (n = 5) or partially (n = 2) recovered after receiving 3 doses of Corticosteroids. Common medications were Natalizumab, Teriflunomide, Dimethyl fumarate, and Rituximab. Also, Interferon beta 1-a was administered to one patient with severe symptoms of numbness. CONCLUSION: Our case series identifies the Sinopharm BBIBP-CorV and the AstraZeneca AZD1222 vaccines as potential triggers for CNS demyelinating diseases. Vaccine administration routines are not affected by these rare and coincidental events. However, these manifestations are not deniable and require serious attention. Further investigations are needed to clarify the actual mechanisms and real associations.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ebrahimi N, Mazdak M, Shaygannejad V, et al. CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series. Vaccine. 2023. PMID: 36635139. doi:10.1016/j.vaccine.2023.01.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。